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Abstract Despite their practical and commercial rel-
evance, there are few reports on the kinetics of growth and
production of Chinese hamster ovary (CHO) cells—the
most frequently used host for the industrial production of
therapeutic proteins. We characterize the kinetics of cell
growth, substrate consumption, and product formation in
naive and monoclonal antibody (mAb) producing recom-
binant CHO cells. Culture experiments were performed
in 125 mL shake flasks on commercial culture medium
(CD Opti CHOTM Invitrogen, Carlsbad, CA, USA)
diluted to different glucose concentrations (1.2–4.8 g/L).
The time evolution of cell, glucose, lactic acid concen-
tration and monoclonal antibody concentrations was
monitored on a daily basis for mAb-producing cultures
and their naive counterparts. The time series were
differentiated to calculate the corresponding kinetic rates
(rx = d[X]/dt; rs = d[S]/dt; rp = d[mAb]/dt). Results
showed that these cell lines could be modeled by Monod-
like kinetics if a threshold substrate concentration value
of [S]t = 0.58 g/L (for recombinant cells) and
[S]t = 0.96 g/L (for naı¨ve cells), below which growth
is not observed, was considered. A set of values for lmax,
and Ks was determined for naive and recombinant cell
cultures cultured at 33 and 37 C. The yield coefficient
(Yx/s) was observed to be a function of substrate
concentration, with values in the range of
0.27–1.08 9 107 cell/mL and 0.72–2.79 9 106 cells/mL
for naive and recombinant cultures, respectively.
The kinetics of mAb production can be described by
a Luedeking–Piret model (d[mAb]/dt = ad[X]/
dt ? b[X]) with values of a = 7.65 9 10-7 lg/cell
andb = 7.68 9 10-8 lg/cell/h for cultures conducted
in batch-agitated flasks and batch and instrumented
bioreactors operated in batch and fed-batch mode.
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Introduction
The number of new biopharmaceuticals currently on
the market is just over 200 (Spadiut et al. 2014; Craven
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et al. 2013). The economic value of these pharmaceu-
ticals continues to expand, with sales that grew from
$30 billion in 2003 (Farges et al. 2008) to $100 billion
by 2012, and are expected to reach $170 billion by
2014 (Spadiut et al. 2014). Among biopharmaceutical
compounds, monoclonal antibodies (mAbs) are an
increasingly accepted class of therapeutics, especially
in the fields of oncology, immunology, and organ
transplant (Elvin et al. 2013). Since their introduction
in 1986, the mAbs have become the dominant product
of the biotherapeutics market (Awotwe-Otoo et al.
2012; Elvin et al. 2013; Spadiut et al. 2014). The
production of biopharmaceuticals, including mAbs,
relies on mammalian cell culture (Dickson 2014;
Craven et al. 2013; Rodrigues et al. 2012), mainly
because many therapeutic proteins require complex
post-translational modifications, and mammalian cells
are uniquely suited to perform these operations
(Craven et al. 2013; Ho et al. 2006).
Currently, Chinese hamster ovary (CHO) cells are
the most commonly used mammalian host cells in the
large-scale commercial production of biopharmaceuti-
cals (Spadiut et al. 2014; Carrillo-Cocom et al. 2014).
Several factors have enabled their adoption as the
industry’s main production host. CHO cells are suitable
for large-scale cultivation, as they grow to very high
density in suspension cultures in bioreactors of up to
10,000 L (Omasa et al. 2010). They are relatively stable
in the expression of heterologous genes over time
(Spadiut et al. 2014; Rodrigues et al. 2012), and they are
able to properly synthesize, fold, glycosylate, and
secrete complex proteins in suspension culture (Ho
et al. 2006; Pascoe et al. 2007), achieving titers in the
range of 5–10 g/L (Elvin et al. 2013; Omasa et al. 2010).
In this contribution, we aim to describe the kinetics
of growth, product production, and substrate con-
sumption in naive and mAb producer CHO cell
cultures, the warhorse in the production of biophar-
maceuticals, using simple kinetic models. Our moti-
vation is practical and simple. Kinetic modeling has
proven to be useful for understanding the relationship
between process variables to improve process perfor-
mance indicators (maximum cell density, product
titter, and productivity) (Almquist et al. 2014; Karim
et al. 2003; Alvarez et al. 2010). However, the
biopharmaceutical industry is a niche wherein math-
ematical modeling has not been widely used. Although
mammalian cells have been employed for many years
in the production of biotherapeutics, information
related to their kinetic parameters is scarce (Zamorano
et al. 2013; Xing et al. 2010). Previously used models
include the Monod-like (Frame and Hu 1991a, b;
Karim et al. 2003) and logistic (Henry et al. 2008)
models for hybridomas; Monod and metabolic flux
(Provost and Bastin 2004); and dynamic metabolic
models for nonproducing CHO cells (Zamorano et al.
2013; Provost and Bastin 2004).
Despite their wide use for more than three decades
in the production of recombinant therapeutics (Kumar
and Singh 2014), there are limited formal reports on
the kinetics of combined cell growth and protein
production in CHO cell cultures: structured kinetic
(Sandadi et al. 2011) and logistic models for r-CHO
producing IgG (Goudar et al. 2009); Monte Carlo
methodology model for CHO cells producing B1
fusion proteins (Xing et al. 2010); and logistic and
regression models for a CHO cell line producing IFN-
! (Farges et al. 2008).
The high added value of biopharmaceuticals is
probably part of the reason why mathematical modeling
has not been used as frequently in biopharmaceutical
mammalian cell culture applications. The focus of the
biopharmaceutical industry has been on the development
of high-production cell lines, culture medium optimiza-
tion, and migration of process design from batch culture
to fed-batch and continuous perfusion systems. However,
some regulatory, economic, and market drivers are
progressively shifting attention to process control and
process optimization (Craven et al. 2013).
These drivers include a stricter regulatory frame-
work for the approval of biopharmaceutical com-
pounds (Shukla and Gottschalk 2013), more focus in a
solid science-based process knowledge or quality-by-
design approach (Craven et al. 2014), and process
control rather than a singular focus on robustness and
reproducibility (Sidoli et al. 2004; Spadiut et al. 2013).
This new context of the pharmaceutical industry also
demands a better understanding of the interdepen-
dence among the key variables in the process. In
addition, the increasing demand for biopharmaceuti-
cals (Meier et al. 2014; Walsh 2010), the increasing
number of companies competing for international
markets (Shukla and Gottschalk 2013), and the
emergence of biosimilars (Kumar and Singh 2014;
Patel et al. 2014) (due to the expiration of the patents
issued for the first round of commercialized mAbs),
have emphasized the need for optimization and better
process control.
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Mathematical modeling can be a useful tool for the
rational design and optimization of cell culture
systems (Almquist et al. 2014). The selection of the
model type depends on the end purpose of the model
and the trade-offs of formulation time, model com-
plexity, and solution time as well as the nature of the
available experimental data (Craven et al. 2013). The
majority of the kinetic models in the literature are
categorized as unstructured because they are not only
the simplest methods for modeling cell culture
systems, but they provide good starting points for
relatively new cell systems where data are limited,
such as in this study’s case. Here, we explore the use of
very simple kinetic models, namely, the Monod-type
model for cell growth and substrate consumption and
the Luedeking–Piret model for production. These
models have been widely used for other cells of
industrial importance, such as bacteria (Gerlach et al.
2014; Singh and Srivastava 2014) and fungi (Gomes
et al. 2014; Slininger et al. 2014), but only modestly
used for mammalian cells (Craven et al. 2013, 2014;
Farges et al. 2008). In industrial practice, simple
models are particularly appreciated; they are easy to
use in real process characterization, online monitor-
ing, process control and process optimization scenar-
ios (Craven et al. 2014; Gerlach et al. 2014). In
addition, they are equally effective for evaluating
different bioreactor designs and devising feeding
strategies (Slininger et al. 2014; Henry et al. 2008).
To our knowledge, this is the first formal report
describing the kinetics of growth, substrate consump-
tion, and product formation in mAb-producing recom-
binant CHO cell cultures using simple models
(Monod-type and Luedeking–Piret).
Materials and methods
Cells and culture mediums
For these experiments, we used a CHO-S clone
engineered in-house (Carrillo-Cocom et al. 2014;
Gonza´lez-Leal et al. 2011) to produce a biosimilar of
the monoclonal antibody infliximab and its native
counterpart (CHO-S line from Invitrogen, Carlsbad,
CA, USA). The cell culture medium consisted of CD
Opti CHO (Invitrogen, Carlsbad, CA, USA) supple-
mented with 8-mM glutamine (Invitrogen, Carlsbad,
CA, USA). Subsequently, we will refer to the naive
CHO cell line and the recombinant cell line derived
from it as n-CHO and r-CHO respectively.
Batch experiments in shake flasks
Batch cultures were performed using naive (n-CHO)
or recombinant cells (r-CHO) in 125-mL shake flasks
with 30-mL working volume. Cultures were seeded at
a viable cell density of *2 9 105 cells/mL and
maintained at 33 or 37 C in an 8 % CO2 humidified
orbital shaking incubator at 125 rpm (Sanyo, San
Diego, CA, USA). Experiments were run at different
initial substrate concentrations, ranging from 1.2 to
4.8 g/L of glucose (1.2, 2.4, 3.6, and 4.8 g/L). The
basal medium was diluted with PBS 19 (Invitrogen,
Carlsbad, CA, USA) to achieve the desired glucose
concentrations. All batch cultures were performed in
triplicate with daily sampling. Cultures were termi-
nated at day 7 for the r-CHO cell line and at day 10 for
the n-CHO line, which corresponded with a viability
drop to below 50 %. All samples for glucose, lactic
acid, and antibody concentration determinations were
centrifuged at 5000 rpm for 5 min. The supernatant
was collected and stored at -20 C until analyzed.
Experiments in instrumented bioreactors
Bioreactor-batch and fed-batch cultures were per-
formed only with the recombinant cell line at basal
medium concentration. Experiments were performed
in 1.6-L bioreactors (DASGIP, Julich, Germany) with
1.0-L working volume. The fed-batch protocol con-
sisted of a temperature reduction (31 C) on the
seventh day and five intermittent feed additions (CD
EfficientFeedTM B, Invitrogen, Carlsbad, CA, USA) of
10 % the initial volume starting on day 1. Cultures
were seeded at a viable cell density of*2 9 105 cells/
mL and maintained at 33 C with an 80-rpm rate of
agitation. Cultures were supplied with a gas mixture
(2 sL/h) consisting of air, oxygen, nitrogen, and
carbon dioxide to maintain a dissolved oxygen satu-
ration of 40 %. All cultures were performed by
duplicate with daily sampling. Batch cultures were
terminated after 10 days and fed-batch cultures after
20 days. Samples for glucose, lactic acid, and anti-
body concentration determinations were collected and
centrifuged at 5000 rpm for 5 min. The supernatant
was stored at -20 C for analysis.
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Analytical methods
Cell density and viability were evaluated via the
trypan blue dye exclusion assay using a flow cytome-
ter (Guava easyCyteTM 8HT Flow Cytometry Sys-
tem, Millipore, Billerica, MA, USA). A 40-mW laser
with a wavelength of 635 nm was used for excitation.
Samples were analyzed with a particle rate of 500
particles/lL and 1000 events. Glucose and lactic acid
concentrations were measured by HPLC using a
Waters chromatography system (model W1515) cou-
pled to a refractive index detector (model W2414,
Waters, Milford, MA). An Aminex HPX 87H (Bio-
Rad, Hercules, CA) column and a 5-mM sulfuric acid
mobile phase were used at a flow rate of 0.6 mL/min
and temperatures of 50 and 60 C in the detector and
oven respectively. An enzyme-linked immunosorbent
assay (ELISA) was used to quantify the active
monoclonal antibody in the collected samples, as
described elsewhere (Carrillo-Cocom et al. 2014).
Kinetics analysis
The viable cell [X] and glucose concentration [S] pro-
files observed in the exponential phase of batch
experiments were fitted to second-order polynomial
equations using Excel Software (Microsoft, Red-
mond, WA, USA). Polynomial equations were derived
to calculate the experimental cell production rate (rx),
where rx = d[X]/dt, and [X] is cell concentration; and
the glucose consumption rate (rs), where rs = d[S]/dt,
and [S] is glucose concentration. The rates were
analyzed to determine the relationships between
substrate consumption and cell concentrations;
namely the cell yield coefficient (Yx/s).
In addition, the values of the specific growth rate at
different initial substrate concentrations were gener-
ated for each cell line using conventional approaches.
Briefly, a first-order growth was assumed to occur
during the initial stage of exponential growth at each
initial substrate concentration (Eq. 1).
d½X=dt ¼ l½X; with ½X ¼ ½Xo @ t ¼ to ¼ 0:0 ð1Þ
In Eq. 1, [X] is the biomass concentration at a given
time, [X]o is the cell concentration at an initial
condition, t is the time, to is the initial time
(corresponding to the beginning of the exponential
growth phase), and l is the specific growth rate with a
constant value at least during the initial portion of the
exponential phase. The integrated version of Eq. 1
renders Eq. 2, a straight-line model.
ln½X ¼ lt þ ln½Xo ð2Þ
Therefore, the value of the specific growth rate (l)
was calculated from the slope of the plots of ln[X]
versus t at each initial substrate concentration value
[S]t. A Monod-type equation (Eq. 3) was used to fit the
values of the specific growth rate (l) at different initial
substrate concentrations.
l ¼ lmax½S  =ðKs þ ½SÞ; with ½S ¼ ½So  ½St
ð3Þ
A Lineweaver–Burk linearization was used to
obtain values for the kinetic parameters: lmax (the
maximum specific growth rate), Ks (the concentration
of substrate at which half the value of lmax was
observed), and the [S]t (the minimum substrate
concentration at which cell growth was observed).
We only considered a particular linear regressions as
valid if r2 was higher than 0.97.
The material balance for substrate consumption
was assumed to be represented by Eq. 4.
rs ¼ d½S=dt ¼ rx=Yx=s ð4Þ
In this equation, rs is the global rate of glucose
consumption, rx is the rate of cell growth, t is time, and
Yx/s is a cell yield coefficient. In agreement with Eq. 4,
the yield coefficient was calculated from the slopes of
rx versus rs plots at different [S]o values.
For the kinetic analysis of mAb production in shake
flasks and bioreactors, the viable cell concentration
profile [X] was fit to a sixth-order polynomial. The
polynomial equation was derived to obtain the exper-
imental cell production rate (rx) at each time. A
Luedeking–Piret-type model (Luedeking and Piret
1959) was proposed for the modeling of antibody
production (Eq. 5).
d½P=dt ¼ rp ¼ arx þ b½X; rx ¼ d½X=dt ð5Þ
Here, [P] is the mAb concentration at a given point,
t is time, rp is the rate of accumulation of product in
time within the reaction vessel, [X] is the cell
concentration at that given time, rx is the rate of cell
growth, and a and b are the Luedeking–Piret
constraints.
Constants were set so that the observed experimen-
tal product profile in fed-batch cultures was closely
1290 Cytotechnology (2016) 68:1287–1300
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approximated by the numerical integration of the
Luedeking–Piret equation (see Eq. 6).
Pn ¼ Pn1 þ arx þ bXð Þ  Dt ð6Þ
Here Pn is the antibody concentration at the present
time step, Pn-1 is the antibody concentration at the
previous time step of the integration, a and b are the
Luedeking–Piret constants, and Dt is the time step of
numerical integration.
In addition, three independent sets of data from the
batch culture experiment of the r-CHO cells conducted
in Erlenmeyer flasks at 37 C were used to adjust the
Monod and Luedeking–Piret values during exponen-
tial growth at this temperature. For this purpose, the
differential material balance equations for cell growth,
substrate consumption, and mAb formation were
numerically integrated using the values of lmax, Ks,
[S]t, Yx/s, and a and b determined at 33 C as an initial
guess. The parameters [S]t and a were kept constant,
while lmax, Yx/s, and b were varied iteratively until a
good agreement between the [X], [S], and [P] exper-
imental time series and the simulation values was
achieved.
Results and discussion
Analysis of concentration profiles at different
substrate concentrations
The culture of CHO cells in commercial culture media
is a relatively well-established protocol among prac-
titioners in biopharmaceutical industry laboratories.
Normally, the culture medium is prepared according to
the recommendation of the manufacturer. However, in
this study, we conducted a series of batch experiments
in shake flasks at different initial substrate concentra-
tions using naive and recombinant cells to evaluate the
dependence of growth kinetics with respect to sub-
strate concentration. For that purpose, we diluted a
commercial culture medium (CD Opti CHO; Invitro-
gen, USA). Triplicate batch culture experiments were
conducted at each culture medium dilution, namely
100, 75, 50, and 25 %, with respect to the concentra-
tion recommended by the manufacturer. Our rationale
was to produce relevant kinetic parameters for a
commercially available and widely used culture
medium (for lab scale and pilot plant applications).
These dilutions approximately correspond to initial
glucose concentrations of 4.8, 3.6, 2.4, and 1.2 g/L,
respectively. Commonly, a bi-phase culture protocol
is used to culture recombinant CHO cells. In a first
culture stage, cells are culture at 37 C to maximize
growth rate. In a second stage, once the maximum cell
density has been reached, the temperature is decreased
to 33 or 31 C to minimize further growth, decrease
product degradation, and favor overall productivity.
However, in our experiments with this particular
recombinant CHO cell line, we have observed best
results (in terms of overall mAb productivity) in
experiments where the cell culture temperature is
maintained at 33 C throughout the entire culture
period. For completeness, in this contribution, we
report cell density profiles and glucose, lactic acid, and
mAb concentration profiles from experiments with
recombinant cells conducted at both 33 and 37 C
(Fig. 1). In general, higher maximum cell densities
and mAb titters are observed at 33 C, although the
glucose concentration profiles are remarkably similar.
Later in this study, we provide a detail kinetic analysis
of the cell growth of both naı¨ve and recombinant cell
cultures at 33 and 37 C.
Figure 2a shows the cell concentration profiles for
both naive and recombinant CHO cells at 33 C. For
the experiments conducted at initial glucose concen-
trations of 4.8, 3.6, and 2.4 g/L, naive and recombi-
nant cell cultures exhibited growth. Negligible cell
growth was observed in experiments at a glucose
concentration of 1.2 g/L. Interestingly, while r-CHO
cells did not exhibit a lag-phase (even at the lowest
initial glucose concentration at which growth was
observed), the naive cells exhibited longer lag-phases
with decreasing initial glucose concentrations. Longer
lag-phases for naı¨ve cells were consistently observed
in experiments conducted at both 33 and 37 C. At this
point, we cannot provide an explanation for this
behavior.
Both cell lines (naı¨ve and recombinant) reached an
average peak cell density of 7 9 106 cells/mL in
undiluted culture medium; no significant difference in
the maximum cell density was observed between
naive and recombinant cultures. For r-CHO cultures,
the peak cell density was typically observed at day 4.
In contrast, such consistency was not achieved on
n-CHO cultures. In r-CHO cultures in undiluted
medium, a sharp decline in viable cell density was
observed after the peak cell density was achieved,
resulting in r-CHO cell cultures lasting 2–3 fewer days
Cytotechnology (2016) 68:1287–1300 1291
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than their naive counterparts. Figure 1b shows the
glucose concentration profiles for naive and recombi-
nant cultures at different culture medium dilutions. In
r-CHO cultures, glucose was depleted by day 6; while
for the n-CHO cultures, complete depletion occurred
by day 8. Clearly, the rate of glucose consumption was
significantly higher in recombinant cultures than in
their naive counterparts. In all the experimental
conditions tested, the rate of glucose depletion was
practically time-independent from the beginning of
the experiment to the complete depletion of substrate.
The lactic acid concentration profiles were similar in
shape to the cell growth curves, but with peak
concentration generally occurring 1–2 days before
the peak in cell density. A similar behavior has been
observed in batch CHO cell cultures in previous
studies (Amanullah et al. 2010; Goudar et al. 2005;
Pascoe et al. 2007). Our experimental results suggest
that in the range of the conditions tested, lactate was
actively produced during the stage of exponential cell
growth for later consumption once the cell density
reached its peak, typical behavior recently studied in
detail by Zagari et al. (2013). In our batch experi-
ments, regardless of the initial glucose concentration,
the maximum lactate concentration did not exceed
1.0 g/L.
Specific production and consumption rates
Table 1 summarizes the rates of growth, substrate
consumption, lactic acid production (or consumption),
Fig. 1 Time evolution of cell, substrate, and lactic acid
concentrations for recombinant CHO cell lines cultured at two
different temperatures [33 C (solid line with square), and
37 C (dashed line with square)], and different initial substrate
concentrations 4.8, 3.6, 2.4, and 1.2 g/L (solid line with square,
solid line with triangle, solid line with circle, solid line with
diamond)
Fig. 2 Time evolution of cell, substrate, and lactic acid
concentrations for naive and recombinant CHO cell lines at
different substrate concentrations. CHO-S (dashed line with
square), r-CHO (solid line with square), and different initial
substrate concentrations 4.8, 3.6, 2.4, and 1.2 g/L solid line with
square, solid line with triangle, solid line with circle, solid line
with diamond). The main difference was that the lag-phase was
reduced for the r-CHO cell line; glucose consumption and lactic
acid production varied similarly according to the cell
concentration
1292 Cytotechnology (2016) 68:1287–1300
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and product formation in each of the experiments run
with n-CHO and r-CHO cultures conducted at 33 C.
Rates were normalized in terms of the accumulated
viable cell count. In the case of glucose consumption,
this analysis showed that glucose consumption rates
progressively decreased (as expected) as glucose
concentration decreased. Two distinct culture phases
were observed in terms of substrate consumption for
recombinant cultures (three for their naive counter-
part). Higher consumption rates during the exponen-
tial growth phase, followed by a drastic decrease of
specific consumption (more than 70 %) once the
culture entered into the late exponential phase. In
naive cultures, a third stage of even lower consump-
tion was discriminated at the end of the exponential
phase. Similarly, in terms of specific rates of lactose
production or consumption, different metabolic stages
of the culture could be distinguished (see also Tsao
et al. 2005). In general, the rate of lactose production
was high at the first half of the exponential phase,
practically proportional to the rate of growth, but
decreased significantly during the second half. This is
consistent with observations from other authors (Za-
gari et al. 2013). After the maximum cell concentra-
tion was achieved (in our batch culture experiments,
this occurred at approximately the point of glucose
depletion), the accumulated lactate was used as a
substrate by the cultures. Note that from day 3 (r-CHO
clone) and day 4 (n-CHO cells), we observed simul-
taneous consumption of lactate and glucose. Interest-
ingly, we observed that in recombinant cultures
exposed to substrate-depleted conditions, the specific
rate of lactate consumption was practically constant
(&0.05 ng/cell/day) and approximately five-times
higher than in naive cell cultures exposed to similar
glucose-depleted conditions. Our experiments also
suggested that the specific rate of mAb production was
higher in experiments at lower initial substrate con-
centrations. Remarkably, the specific production rate
practically doubled its value in experiments at
[S]o = 1.3 g/L with respect to those conducted in
undiluted medium (1.015 vs 0.58 pg/cell/day).
Overall, our results showed that growth was a
strong function of substrate concentration for naive
and recombinant CHO cells. With decreasing initial
glucose concentration (in the window of 2–4 g/L), the
rate of cell growth, the maximum cell density, and
lactic acid production progressively decreased. At
glucose concentrations lower than 1.2 g/L, negligibleT
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cell growth rates (and glucose consumption rates)
were observed. As expected, the glucose consumption
rates observed in recombinant cultures were higher
than in naive ones. In the absence of glucose
supplementation, both naive and recombinant cultures
were able to consume lactate. Surprisingly, naive
cultures exhibited a longer lag-phase and reached their
highest cell density later than the recombinant cul-
tures. The value of the maximum cell density was
approximately the same for naive and recombinant
cultures.
Differences related to range of growth, glucose
consumption, and lactate production between naive
and transformed cell clones have been reported in
other studies (Ho et al. 2006; Pascoe et al. 2007). Here,
we established a direct comparison in the context of
mAb production of recombinant and naive cells
exposed to the same experimental conditions and
derived from the same commercial cell line. In the
following section, the dependence of the growth rate
as a function of glucose concentration will be char-
acterized in more detail, and a Monod-type model for
CHO cells will be proposed.
A simple Monod-type kinetic model for CHO cell
growth rate
The CHO cell line was developed in 1957 (Jayapal
et al. 2007; Tjio and Puck 1958), and the production of
monoclonal antibodies in CHO cells was reported in
1990 and 1991 (Page and Sydenham 1991; Wood et al.
1990). Surprisingly, the simple kinetic models widely
used to describe the growth and production of other
cells of commercial interest have not been widely used
to study the dynamics of growth, production, and
substrate consumption in CHO cell cultures. To further
study the dependence of cell growth from substrate
concentrations, we chose a Monod-type model; Monod
models have a proven record as a useful model across
other biological systems and scales (e.g., Craven et al.
2013). To our knowledge, there are no literature reports
on the kinetic parameters from CHO cell batch culture
related to mAb production.
From the cell growth curves in Fig. 1a, we calcu-
lated the average specific growth rate [l (h-1)] during
the exponential phase for every initial substrate
concentration for experiments at both 33 and 37 C.
We observed that cell growth was a first-order process
(Eq. 1) with respect to cell concentration, at least at
the beginning of the exponential growth phase for each
initial substrate concentration. We used Eq. 2, the
integrated version of Eq. 1, to calculate the initial
specific growth rate (l) from the slope of the plot of
ln[X] versus time constructed at each initial substrate
concentration. Figure 3 shows the values of l as a
function of initial glucose concentration for naive and
recombinant cell cultures. The shape of the curve
suggests a Monod-type behavior. However, the curves
do not originate from the zero substrate value.
Therefore, a useful growth model requires the inclu-
sion of a threshold substrate parameter. This type of
growth limitation has been referred to in literature as a
kinetic growth limitation (Sidoli et al. 2004; Kovarova
et al. 1996). The existence of this substrate threshold
has been justified based on maintenance energy and
thermodynamic arguments (Kovarova et al. 1996;
Ribes et al. 2004). Additional experiments were
µ 
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)
µ 
(h
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)
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Fig. 3 Specific growth rate at different initial substrate
concentrations. For a naı¨ve and b recombinant cell lines, a
threshold substrate value of 0.6 g/L was identified. Kinetic
parameters obtained via Lineweaver–Burk linearization,
accounting for the threshold substrate, were lmax 0.050 h
-1
and Ks 2.058 g/L for the n-CHO cell line and lmax 0.043 h
-1
and Ks 0.929 g/L for the r-CHO cell line
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carried out with lower initial glucose concentrations,
namely 0.65, 0.45, and 0.25 g/L (data not shown).
Results indicated that growth stopped below 0.60 g/L.
Although the Monod model imposes the growth
rate at zero only if the substrate concentration becomes
zero, which was previously determined untrue for our
particular cell lines, it is generally recognized that
threshold substrate concentrations exist at levels
below where any substrate consumption occurs (Ribes
et al. 2004). Thus, the Monod model has been
previously modified to account for these deviations
(Frame and Hu 1991b; Kovarova et al. 1996; Ribes
et al. 2004). For the present work, the model shown in
Eq. 3 provided an excellent fit to our experimental
data and was consistent with our experimental obser-
vation of existence of a substrate threshold for cell
growth.
l ¼ lmax½S  =ðKs þ ½SÞ; with ½S ¼ ½So  ½St
ð3Þ
In this model, l is the specific growth rate of the
cells, lmax is the maximum specific growth rate, [S]
* is
the above-the-threshold substrate concentration, [S]t is
the substrate threshold concentration, and Ks is the
half-velocity constant. The kinetic parameter values
for this Monod-type model for both naive and
recombinant CHO cells were obtained using a Line-
weaver–Burk linearization strategy (Table 2; Fig. 3).
Values of lmax = 0.050 h
-1 and Ks = 1.023 g/L
were estimated for the naive cell cultures at 37 C.
For experiments at 33 C, this set of parameter values
changes significantly; lmax = 0.038 h
-1 and
Ks = 0.286 g/L. The substrate threshold value to
initiate cell growth also changes significantly;
[S]t = 0.96 g/L in experiments at 33 C and
[S]t = 0.96 g/L in experiments at 37 C. Interest-
ingly, the Monod-type kinetic values for recombinant
cells do not change significantly as a function of
temperature (Fig. 3), and for all practical purposes, a
single set of parameters (lmax = 0.040 h
-1;
Ks = 0.664 g/L; [S]t = 0.58 g/L) can be used to
describe recombinant cell growth at 33 and 37 C.
As expected, higher specific rate values were deter-
mined for naive cell cultures at 37 C. Intriguingly, a
lower Ks value was observed in r-CHOs (at both 33
and 37 C) than in n-CHOs at 37 C, indicating that a
lower substrate concentration is needed in recombi-
nant cultures to reach at least half of the maximum rate
of growth. These kinetic parameter values were
consistent with the reported ranges for lmax for naive
CHO Cells (0.020–0.060 h-1) (Craven et al. 2013;
Sandadi et al. 2011; Xing et al. 2010; Goudar et al.
2009; Farges et al. 2008) and slightly higher than
values reported for other recombinant CHO cell lines
(0.025–0.035 h-1) (Craven et al. 2013; Xing et al.
2010; Goudar et al. 2009; Farges et al. 2008).
Estimation of yield coefficients Yx/s
The cell production rate (rx) and the substrate
consumption rate (rs) were calculated as the analytical
derivative of second-order polynomial equations fitted
to time series data of [X] and [S] during the
exponential growth phase of naive and recombinant
cultures. The cell/substrate yield coefficient (Yx/s)
resulted from the reciprocal of the slope for the cell
Table 2 Kinetic parameters determined from batch experiments for naive (n-CHO) and recombinant (r-CHO) cell cultures at 33 and
37 C
Parameter n-CHO cells (@ 33 C) n-CHO cells (@ 37 C) r-CHO cells (@ 33 C) r-CHO cells (@ 37 C)
lmax (h
-1) 0.038 0.05 0.040 0.040
Ks (mg/mL) 0.286 1.023 0.664 0.664
[S]t (mg/mL) 0.96 0.58 0.58 0.58
Yx/s (cell/mg) &6.08 9 10
6a &6.08 9 106a &2.59 9 106b 1.70 9 106
a (lg/cell) 0 0 7.65 9 10-7 7.65 9 10-7
b (lg/cell/h) 0 0 7.65 9 10-8 1.38–3.38 9 10-8c
a Value ranges from 2.69 to 10.8 9 106 (see Table 2)
b Value ranges from 0.71 to 2.79 9 106 (see Table 2)
c No unique value was capable of fitting experimental {t,[X],[P]} data for different sets
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production rate versus the substrate consumption
curve, see Eq. 4. Our results suggested that the
cell/substrate yield coefficient was not constant, but
was a function of the substrate concentration: at higher
glucose concentrations, higher conversion efficiencies
were observed. For the calculation of the yield
coefficient of the recombinant CHO cell line, we
assumed that the substrate consumption during the first
7 days of culture was devoted to cell growth; that is,
no significant glucose consumption was a result of
product assembly. This assumption was based on the
fact that the mAb concentration at day 7 was still
modest (10–15 mg/L) compared to the maximum
production potential of this cell line in fed-batch
cultures with supplementation (final mAb titer of
250 mg/L, data not shown). Additionally, product
concentration was minimal compared to the initial
substrate concentrations; 10–15 mg/L was the final
mAb titer compared to 4 g/L of initial glucose.
Therefore, very little substrate must have been used
for product generation during the first 7 days of
culture. Furthermore, by comparing the values for the
yield coefficients between both cell lines (Table 3), we
observed that the yield coefficients corresponding to
the naive cells were significantly higher than those of
the recombinant cell line. Our results suggest that in a
recombinant cell, a significant portion of substrate is
used to sustain protein production even at growth
stages where protein expression is still not significant.
In producer cells, the more complex cell metabolism
associated with the synthesis capability of an exoge-
nous protein implies higher substrate demands.
Modeling of mAb production in shake flasks
Figure 4a shows the cell and mAb profiles for typical
batch processes conducted in shake flasks. In our
experiments, cultures were typically maintained for
160–190 h. On average, the maximum cell densities of
7 9 106 cells/mL and final mAb titers of 60 mg/L
were achieved. Typically, in mAb production pro-
cesses, product accumulation continues after the cell
density peaks (Templeton et al. 2013). In our batch
experiments, 70 % of the final mAb titer was gener-
ated during the cell death phase of the culture.
We also studied the kinetics of the process of
monoclonal antibody production and their relationship
with the rate of cell growth. The production kinetics of
mAb are highly cell-line dependent. Several reports
have documented that antibody production is practi-
cally independent of the cell growth and substrate
Table 3 Cell/substrate yield coefficient Yx/s for naive (n-
CHO) and recombinant (r-CHO) cell lines calculated from
batch experiments conducted at 33 C at different initial sub-
strate concentrations
[S]o (mg/mL) Yx/s
n-CHO-S (cells/mg)
Y x/s
r-CHO (cells/mg)
4.8 1.08E?7 2.79E?6
3.6 7.25E?6 3.19E?6
2.4 3.58E?6 1.81E?6
1.2 2.69E?6 7.18E?5
Fig. 4 A simple Luedeking–Piret model describes the relation-
ship between the rate of growth, the viable cell concentration,
and the rate of mAb production in a batch experiments
performed in Erlenmeyer flasks at [S]o = 4.8 g/L (undiluted
medium); b batch experiments run in 1.0-L instrumented
bioreactor at [S]o = 4.8 g/L; and c fed-batch experiments run
in 1.5-L (final volume) instrumented bioreactors. Experimental
viable cell data (black dot) was fit to a fifth-order polynomial
(dashed line). Adequate fit (dark line) to the experimental mAb
concentrations [mAb] (gray dot) was achieved using the same
a,b-parameter set with a = 7.65 9 10-7 lg/cell/h and
b = 7.68 9 10-8 lg/cell for all three experimental scenarios
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consumption rates (Henry et al. 2008; Sidoli et al.
2004). However, results from previous experiments
with this recombinant CHO cell line suggested that it
followed mixed-mode production kinetics, where at
any given time the rate of product formation depends
on the rate of cell growth and the current viable cell
concentration. As a first approximation in this study,
we choose the Luedeking–Piret model to describe the
kinetics of product formation in the recombinant cell
cultures (Eq. 5). This model is based on the premise
that the rate of product synthesis can be a function of
both cellular density ([X]) and the rate of cell growth
(rx). We also assumed that a Luedeking–Piret model
could describe the kinetics of mAb throughout the
entire duration of the cell culture.
To determine values for the parameters of the
model, we followed a straight-forward approach. The
values of a and b were chosen to fit several experi-
mental data sets of cell concentration and mAb
production profiles. We fit polynomial models to the
experimental profiles of cell density versus time
observed in r-CHO cell cultures. From these polyno-
mials, values of the cell concentration ([X]) and the
rate of cell growth (rx) at any given time were
calculated. We used these values ([X], rx) together
with a and b sets to numerically integrate the
Luedeking–Piret equation (see Eq. 6). The best fit
(shown as a dashed line in Fig. 4) was achieved using
the values of a = 7.65 9 10-7 lg/cell/h, and
b = 7.68 9 10-8 lg/cell. These a and b values can
be used to accurately reproduce data obtained in
experiments where the initial substrate concentration
ranges from 2.4 to 4.5 g/L (undiluted medium).
The absence of both internal stirring and sparging in
shake flasks has been shown to generate culture
conditions substantially different from those in biore-
actors (Sieck et al. 2013). Duplicate batch processes
were performed with recombinant CHO cell cultures
in 1.6-L (1.0-L w/v) bioreactors at an undiluted
medium concentration. Figure 3b shows the cell and
mAb profiles for a representative batch process of
approximately 250 h, with a peak cell density of
4 9 106 cells/mL on day 7, and a final mAb titer of
40 mg/L. As compared to the cell profiles observed in
shake flasks, there was a lag-phase up to 3 days, which
resulted in longer processes.
In this set of bioreactor experiments, the mAb
concentration time series, was well described by a
Luedeking–Piret model. The values of
a = 7.65 9 10-7 lg/cell/h and b = 7.68 9 10-8 -
lg/cell that produced the best fit for shake flask batch
experiments, fit the experimental data well (Fig. 4b).
We also validated the use of this parameter set in
fed-batch cultures in instrumented bioreactors, con-
ducted under a dual phase culture strategy: (a) a first
period of cell growth at 37 C followed by (b) a mAb
production stage at 33 C. As before mentioned, this
protocol more accurately represents the standard
practice for recombinant CHO cell cultures. Figure 4c
shows the cell and mAb profiles for a representative
fed-batch experiment conducted in a 1.5-L instru-
mented bioreactor. In this case, process duration was
approximately 450 h, with a peak cell density of
6 9 106 cells/mL on day 8 and a final mAb titer of
90 mg/L. The culture was set to 37 C for the first
7 days of culture. At day 7, the temperature set point
was decreased to 33 C.
As a direct result of the temperature shift and fed
batch protocol, the cell production rate at the late
exponential growth phase was reduced, and a high
viable cell density was maintained for 5 days, result-
ing in a prolonged culture. We observed a shift from
peak cell density to peak antibody production. There
was also a twofold increase in mAb production (from
40 to 90 mg/L). The Luedeking–Piret model previ-
ously tested for batch processes (in shake flasks and
bioreactors) fit the experimental data (shown as a
dashed line in Fig. 3c), while maintaining the same
Luedeking–Piret constants.
Monod and Luedeking–Piret parameters
at different temperatures
For the clone used in this study, we found that higher
final mAb titers can be obtained by setting the culture
temperature at 33 C during exponential growth and
later decreasing it to 31 C or by maintaining the
temperature at 33 C during the entire culture. The
Monod parameters that we reported in a previous
section are valid for exponential growth at 33 C. The
proposed parameter values for the Luedeking–Piret
model fit reasonably well with several independent
experimental data sets in the range of 31–33 C.
However, different protocols are used to culture CHO
cells in commercial practice and academic work. Not
infrequently, a temperature of 37 C is used during the
exponential growth period normally corresponding to
the first 7 days of culture. We used three independent
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sets of data from the batch culture experiment of
r-CHO cells at 37 C to adjust the Monod and
Luedeking–Piret values during exponential growth at
this temperature. The differential material balance
equations for cell growth, substrate consumption, and
mAb formation were numerically integrated. The
parameter values were determined for growth, sub-
strate consumption, and product formation for cultures
at 33 C as an initial guess. Results from the numerical
integration were compared to [X], [S], and [P] exper-
imental time series. We observed that, by modifying
the values of lmax and Yx/s, an appropriate fit was
achieved with respect to the experimental time series
{t,[X],[S]} of several experimental data sets at 37 C.
The values of Ks and [S]t calculated from experiments
at 33 C were used to properly fit the data at 37 C.
However, for mAb production in batch experiments at
37 C, we were unable to simulate different experi-
mental sets using the same a and b values from the
Luedeking–Piret model. The time series of [mAb],
[X], and [S] versus time can be reasonably described
during batch cultivation experiments at 37 C by
keeping the value of a = 7.65 9 10-7 (the same
values calculated from experiments at 33 C) and
setting b in the range of 1.30–3.50 9 10-8 cell/lg.
The inclusion of an inhibitory effect of lactate
concentrations in mAb production should improve
the performance of the model at T = 37 C. In
Table 2, we summarized all the kinetic parameters
determined for naive and recombinant cultures at 33
and 37 C.
Conclusions
In summary, we studied the kinetics of cell growth,
glucose consumption, and product formation in mAb-
producing recombinant CHO cells at 33 C, and
compared them to their naive counterparts. It was
found that, for these specific cell lines, simple kinetic
models could explain cellular growth, glucose con-
sumption, and product formation. For the cellular
growth, a Monod-type model was proposed with a
modification to account for a threshold glucose
concentration of 0.6 g/L. The overall rate of glucose
consumption can be properly described using a
constant cellular yield. Product formation was found
to be related to the rate of cell growth and the cellular
density itself through a Luedeking–Piret-type model.
We determined the Luedeking–Piret-type constants
for batch cell cultures conducted in shake flasks and
stirred bioreactors. The set of kinetic parameters
calculated from batch cultures properly described
growth, glucose consumption, and mAb formation in
fed-batch processes.
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